Total Payments
$5,579
2024 Payments
$675.31
Companies
47
Transactions
355
Medicare Patients
3,999
Medicare Billing
$516,319
Payment Breakdown by Category
Food & Beverage$5,489 (98.4%)
Gifts$59.40 (1.1%)
Education$31.36 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,489 | 349 | 98.4% |
| Gift | $59.40 | 1 | 1.1% |
| Education | $31.36 | 5 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $877.64 | 59 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $701.08 | 25 | $0 (2022) |
| Lilly USA, LLC | $598.72 | 43 | $0 (2024) |
| Amgen Inc. | $395.56 | 31 | $0 (2024) |
| Mannkind Corporation | $348.13 | 20 | $0 (2024) |
| Novo Nordisk Inc | $294.29 | 20 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $263.83 | 16 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $256.49 | 18 | $0 (2024) |
| Corcept Therapeutics | $238.68 | 16 | $0 (2021) |
| IBSA Pharma Inc. | $193.26 | 16 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $675.31 | 39 | Lilly USA, LLC ($196.32) |
| 2023 | $601.90 | 36 | SANOFI-AVENTIS U.S. LLC ($90.76) |
| 2022 | $561.34 | 38 | SANOFI-AVENTIS U.S. LLC ($129.83) |
| 2021 | $582.45 | 42 | Lilly USA, LLC ($154.15) |
| 2020 | $1,165 | 79 | AstraZeneca Pharmaceuticals LP ($220.18) |
| 2019 | $431.31 | 31 | SANOFI-AVENTIS U.S. LLC ($83.95) |
| 2018 | $718.59 | 44 | AstraZeneca Pharmaceuticals LP ($176.68) |
| 2017 | $843.68 | 46 | AstraZeneca Pharmaceuticals LP ($236.37) |
All Payment Transactions
355 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: DIABETES | ||||||
| 11/22/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/06/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: Biological | ||||||
| 11/05/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/04/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Diabetes | ||||||
| 10/29/2024 | RECORDATI_RARE_DISEASES_INC. | SIGNIFOR LAR (Drug), ISTURISA | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: ENDOCRINE AGENT | ||||||
| 10/10/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: Biological | ||||||
| 10/09/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Diabetes | ||||||
| 10/09/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: DIABETES MEDICINE | ||||||
| 09/04/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: Diabetes | ||||||
| 08/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: DIABETES | ||||||
| 08/21/2024 | CeQur Corporation | CeQur Simplicity (Device) | Food and Beverage | Cash or cash equivalent | $14.53 | General |
| Category: Diabetes | ||||||
| 08/15/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: DIABETES MEDICINE | ||||||
| 08/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 07/26/2024 | PFIZER INC. | SOMAVERT (Drug) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 07/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/10/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Diabetes Care | ||||||
| 07/04/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Diabetes | ||||||
| 06/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Diabetes | ||||||
| 05/29/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 05/29/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: Diabetes | ||||||
| 05/23/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 05/10/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,032 | 2,253 | $188,218 | $133,407 |
| 2022 | 14 | 1,008 | 2,250 | $186,846 | $128,011 |
| 2021 | 15 | 996 | 2,373 | $193,707 | $136,113 |
| 2020 | 16 | 963 | 2,167 | $182,422 | $118,789 |
Total Patients
3,999
Total Services
9,043
Medicare Billing
$516,319
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 216 | 610 | $53,736 | $38,038 | 70.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 178 | 371 | $47,870 | $33,012 | 69.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 120 | 299 | $25,430 | $19,149 | 75.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 136 | 147 | $23,545 | $15,401 | 65.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 98 | 380 | $17,480 | $13,703 | 78.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 27 | $4,674 | $3,276 | 70.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 37 | 68 | $3,654 | $2,659 | 72.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 14 | $3,318 | $1,972 | 59.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $2,917 | $1,791 | 61.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 15 | $1,830 | $1,435 | 78.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 11 | 11 | $850.96 | $833.91 | 98.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 13 | 16 | $1,040 | $702.57 | 67.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 109 | 229 | $687.00 | $673.26 | 98.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 36 | 40 | $845.00 | $427.35 | 50.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 11 | 11 | $341.00 | $334.18 | 98.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 213 | 597 | $51,939 | $35,345 | 68.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 157 | 291 | $37,248 | $24,986 | 67.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 119 | 422 | $35,870 | $24,519 | 68.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 100 | 119 | $19,040 | $13,113 | 68.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 87 | 295 | $13,570 | $9,265 | 68.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 43 | $10,191 | $6,873 | 67.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 48 | $5,856 | $4,012 | 68.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 45 | 77 | $4,075 | $3,078 | 75.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 25 | $4,275 | $2,985 | 69.8% |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | Office | 2022 | 21 | 21 | $1,459 | $1,365 | 93.5% |
About Dr. Ara Apelian, MD
Dr. Ara Apelian, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Piscataway, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679687073.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ara Apelian, MD has received a total of $5,579 in payments from pharmaceutical and medical device companies, with $675.31 received in 2024. These payments were reported across 355 transactions from 47 companies. The most common payment nature is "Food and Beverage" ($5,489).
As a Medicare-enrolled provider, Apelian has provided services to 3,999 Medicare beneficiaries, totaling 9,043 services with total Medicare billing of $516,319. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Piscataway, NJ
- Active Since 08/19/2006
- Last Updated 07/09/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1679687073
Products in Payments
- FARXIGA (Drug) $522.28
- JARDIANCE (Drug) $406.39
- AFREZZA (Drug) $348.13
- SOLIQUA 100/33 (Biological) $320.26
- TRULICITY (Drug) $251.79
- Korlym (Drug) $238.68
- JANUVIA (Drug) $238.16
- Tirosint (Drug) $193.26
- Repatha (Biological) $188.21
- LOKELMA (Drug) $178.80
- TOUJEO (Drug) $147.83
- SOLIQUA (Drug) $144.14
- TZIELD (Biological) $114.97
- Ozempic (Drug) $113.60
- Kerendia (Drug) $112.17
- BAQSIMI (Drug) $109.90
- CYCLOSET (Drug) $100.17
- FREESTYLE LIBRE 3 (Device) $89.69
- Victoza (Drug) $79.70
- Prolia (Biological) $65.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.